Editor, OncLive®
Caroline Seymour is your initial point of contact for the OncLive® podcast, OncLive On Air™. She joined the company in 2018 as an assistant editor, with expertise in video production and print/digital publication. Email: cseymour@onclive.com
FDA Approvals Augment Advances Made in the DLBCL Armamentarium
August 11th 2020John M. Pagel, MD, PhD, discusses current treatment approaches in frontline and relapsed/refractory DLBCL and provides insight on some of the agents that are generating excitement in the relapsed/refractory setting.
Read More
Refining Risk-Adapted Therapy in ER+ Breast Cancer
August 7th 2020Eleftherios (Terry) P. Mamounas, MD, MPH, FACS, discusses the risk of late recurrence in early breast cancer, current approaches to extended adjuvant endocrine therapy, and ongoing research evaluating assays aimed at capturing both the risk of late recurrence and benefit from extended endocrine therapy.
Read More
Navigating New Immune-Based Combinations in Advanced NSCLC
July 29th 2020Joshua K. Sabari, MD, discusses a number of immunotherapy regimens that have emerged in the frontline setting for patients with driver-negative advanced non–small cell lung cancer; however, for many patients, the decision comes down to pembrolizumab monotherapy or pembrolizumab in combination with platinum-doublet chemotherapy.
Read More
Moving Toward Newfound Diagnostic, Treatment Paradigms in Lung Cancer
July 23rd 2020Ignacio I. Wistuba, MD, discusses the clinical importance of histological subtyping of lung cancer and additional parameters such as driver alterations, alternative methods for molecular testing, and immunotherapy-related biomarkers have strengthened the diagnostic and treatment paradigms in lung cancer.
Read More
NCCN Publishes Guidelines Listing Pexidartinib as Category 1 Recommended Therapy in TGCT
July 20th 2020The National Comprehensive Cancer Network recently published updated Clinical Practice Guidelines in Oncology for Soft Tissue Sarcoma, listing pexidartinib as a systemic treatment for patients with tenosynovial giant cell tumor.
Read More
Trastuzumab Deruxtecan Shows Broad Benefit in Metastatic HER2+ Breast Cancer
July 13th 2020William J. Gradishar, MD, discusses the activity of trastuzumab deruxtecan in patients with metastatic HER2-positive breast cancer and the importance of building experience with the drug before evaluating it in combination or moving it into earlier lines of therapy.
Read More
Investigators Leverage Radiomics to Risk Stratify Patients With Early-Stage Lung Cancer
July 9th 2020Matthew Schabath, PhD, discusses the use of peritumoral and intratumoral radiomic features, where investigators created a model that identified patients with early-stage lung cancer at high risk of experiencing poor survival outcomes.
Read More
ASCO 2020 Ushers in a Number of New Targeted Therapy Developments in NSCLC
July 5th 2020Paul A. Bunn, Jr, MD, discusses how fam-trastuzumab deruxtecan-nxki could provide patients with metastatic non–small cell lung cancer who harbor HER2 exon 20 insertion mutations and high HER2 expression a more specific and less toxic treatment compared with platinum doublet chemotherapy.
Read More
Early Biomarker Data Provide Framework for Precision Medicine-Based Trials in Prostate Cancer
July 2nd 2020Liquid biopsy with circulating tumor DNA could help alleviate some of the challenges of tissue biopsy in prostate cancer, and in doing so, lead to a better precision medicine model in the field.
Read More
Atezolizumab/Bevacizumab Shows Comparable Activity in Older Patients With Advanced HCC
July 1st 2020The combination of atezolizumab and bevacizumab demonstrated comparable clinical activity and safety versus sorafenib in older and younger patients with previously untreated, unresectable hepatocellular carcinoma.
Read More
Leonard Leads Discussion on Latest Developments in Leukemias and Lymphomas
June 26th 2020Data in Richter’s transformation, Hodgkin lymphoma, Waldenström macroglobulinemia, and indolent lymphoma were presented at the 2020 ASCO Virtual Scientific Program, and although not entirely practice changing, are deserving of attention.
Read More
Contemporary Considerations for Cancer Care in the COVID-19 Era
June 26th 2020The downstream effects of the coronavirus disease 2019 on patients with cancer have become apparent over the past few months, and the onus is on the field to provide clinical guidance on best practices in the absence of definitive data.
Read More
Multiple Myeloma Paradigm Moves Forward With Promising Portfolio
June 25th 2020There was no shortage of exciting developments at the 2020 ASCO Virtual Scientific Program in multiple myeloma. Peter Voorhees, MD, explained all of the pivotal data in myeloma therapeutics in a virtual presentation during the 2020 ASCO Direct Highlights webcast.
Read More
Liu Lends Insight on Highlights From ASCO 2020 in Lung Cancer
June 25th 2020A number of influential clinical trials were presented during the 2020 ASCO Virtual Scientific Program, 8 of which Stephen Liu, MD, discusses in depth in a virtual presentation during the 2020 ASCO Direct Highlights webcast.
Read More
Tucatinib Produces Potent Preclinical Antitumor Activity, CNS Penetrance in HER2+ Breast Cancer
June 23rd 2020The HER2-selective TKI tucatinib (Tukysa) demonstrated potent antitumor activity alone and in combination with ado-trastuzumab emtansine (T-DM1; Kadcyla) in HER2-overexpressing breast cancer cell lines and xenograft models.
Read More